sitagliptin

Known as: Sitagliptin [Chemical/Ingredient], 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine, Sitagliptinum 
An orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4… (More)
  • figure 1
  • figure 2
  • table 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
CONTEXT Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades the incretins, glucagon-like… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Agonists of the glucagon-like peptide-1 (GLP-1) receptor provide pharmacological levels of GLP-1 activity, whereas… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVE Cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type 2 diabetes without… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2… (More)
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE To examine the efficacy and safety of once-daily oral sitagliptin as monotherapy in patients with type 2 diabetes… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients with type 2… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
Is this relevant?
Review
2006
Review
2006
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE The efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy… (More)
Is this relevant?